All In Biotech

Drug Trial Radar · NCT06268574

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

A Multicenter, Open-Label Clinical Trial of RVU120 in Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia With or Without NPM1 Mutation (RIVER-52)

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

62

Actual

Start

Jan 23, 2024

Primary completion

Jun 30, 2025

Study completion Sep 5, 2025

Sponsor

Lead sponsor
Ryvu Therapeutics SAIndustry
Sponsor type
Industry
First posted
Feb 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to assess the safety, tolerability, anti-tumor activity (efficacy), pharmacokinetics (PK), and pharmacodynamics (PD) of the agent RVU120 when administered to adult patients with relapsed or refractory acute myeloid leukemia (AML) or relapsed or progressing high-risk myelodysplastic syndrome (HR-MDS) and who have no alternative therapies available. The study consists of two parts. Part 1 will assess the safety and tolerability of the dosages given and the level of anti-tumor activity or clinical response. Based on the results from part 1 the study will continue to enrol patient into Part 2 which will continue to evaluate safety and tolerability and anti-tumor activity in a larger number of patients.

Conditions

  • Acute Myeloid Leukemia (AML)
  • High-risk Myelodysplastic Syndrome

Interventions

  • RVU120Drug

    RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Remission (CR), with and without measurable residual disease (MRD)Time frame: 12 months

Locations

41 sites in 4 countries. Site status is shown where the registry gives one.

  • Centre Hospitalier Universitaire Grenoble Alpes

    La Tronche, France

  • Centre Hospitalier Le Mans

    Le Mans, France

  • Centre Hospitalier Universitaire de Lille (CHU Lille)

    Lille, France

  • Institut Paoli Calmettes (IPC)

    Marseille, France

  • Centre Hospitalier Universitaire (CHU) de Nice - Hopital L'Archet I

    Nice, France

  • Centre Hospitalier Universitaire de Nimes (CHU) - Institut de Cancerologie du Gard

    Nîmes, France

  • Publique-Hopitaux de Paris (AP-HP) - Hopital Saint-Louis

    Paris, France

  • UNICANCER - Centre Henri-Becquerel

    Rouen, France

  • Azienda Ospedaliero Universitaria Delle Marche

    Ancona, Italy

  • Univerisity of Bologna Policlinico Sant'Orsola

    Bologna, Italy

  • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

    Brescia, Italy

  • Careggi University Hospital

    Florence, Italy

  • Ospedale Vito Fazzi Lecce

    Lecce, Italy

  • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

    Meldola, Italy

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, Italy

  • Azienda Ospedaliera Policlinico Universitario Tor Vergata

    Roma, Italy

  • Humanitas Mirasole S.p.A.

    Rozzano, Italy

  • Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino

    Turin, Italy

  • Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej

    Biała Podlaska, Poland

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland

  • Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

    Gliwice, Poland

  • Pratia Hematologia Sp. z o.o.

    Katowice, Poland

  • Szpital Wojewodzki Im. Dr. Ludwika Rydygiera w Suwalkach

    Suwałki, Poland

  • MICS Centrum Medyczne Toruń

    Torun, Poland

  • Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego

    Wałbrzych, Poland

  • Instytut Hematologii I Transfuzjologii

    Warsaw, Poland

  • Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy

    Warsaw, Poland

  • Dolnoslaskie Centrum Onkologii Pulmonologii i Hematologii

    Wroclaw, Poland

  • Szpital Uniwersytecki Imienia Karola Marcinkowskiego w Zielonej Gorze Sp. z o. o.

    Zielona Góra, Poland

  • MTZ Clinical Research

    Warsaw, Mazowieckie Województwo, Poland

  • Hospital de la Santa Creu i de Sant Pau

    Barcelona, Spain

  • Hospital del Mar

    Barcelona, Spain

  • Institut Catala d'Oncologia Hospitalet

    Barcelona, Spain

  • Complejo Hospitalario De Caceres - Hospital General San Pedro De Alcantara

    Cáceres, Spain

  • Hospital Universitario La Paz (HULP)

    Madrid, Spain

  • MD Anderson Cancer Center Madrid

    Madrid, Spain

  • Hospital Regional Universitario de Málaga

    Málaga, Spain

  • Clinica Universidad de Navarra

    Pamplona, Spain

  • Virgen del Rocío University Hospital

    Seville, Spain

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.